BioSpace News Archive

Fresenius Medical Care, the world’s leading provider of products and services for individuals with renal diseases, announced the company has received U.S. Food and Drug Administration 510 clearance for the company’s 5008X Hemodialysis System.

For the eighth consecutive year, McKesson has received approval from the Centers for Medicare & Medicaid Services to participate in the Merit-based Incentive Payment System as a Qualified Clinical Data Registry.

Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) today announced its operating and financial results and provided a business update for the company’s third fiscal quarter ended December 31

FibroBiologics announced the issuance of three patents from the United States Patent Office (USPTO) to add to its portfolio.

BioCorRx Inc. announced that its subsidiary BioCorRx Pharmaceuticals Inc., has appointed Kate Beebe DeVarney, Ph.D. to its Board of Directors.

MIVI Neuroscience, Inc. (Eden Prairie, MN) announces the primary endpoint results of its EvaQ Trial, a prospective, multi-center, global, single arm, FDA-regulated IDE trial study to evaluate the safety and effectiveness of the MIVI Q™ Revascularization System for treating acute ischemic stroke.

Cell BioEngines, Inc. announced that Dr. Ajay Vishwakarma, Founder and CEO of Cell BioEngines, will be presenting at the BIO CEO & Investor Conference at 2:00 p.m. EST on Monday, February 26, 2024.

Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced that it will release financial results for the fourth quarter and full year of 2023 after the market close on March 4th, 2024.

Athira Pharma, Inc. announced publication of research highlighting the neuroprotective and anti-inflammatory effects of ATH-1105 in preclinical models of amyotrophic lateral sclerosis.

Surgery Partners, Inc. (NASDAQ:SGRY) (“Surgery Partners” or the “Company”), a leading short-stay surgical facility owner and operator, announced the Company will release its fourth quarter 2023 results before the market opens on Monday, February 26, 2024, to be followed by a conference call at 8:30 a.m. (Eastern Time)